These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27450739)

  • 1. Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases.
    Sosne G; Rimmer D; Kleinman HK; Ousler G
    Vitam Horm; 2016; 102():277-306. PubMed ID: 27450739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries.
    Sosne G; Kleinman HK
    Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5110-7. PubMed ID: 26241398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymosin beta 4 and the eye: the journey from bench to bedside.
    Sosne G
    Expert Opin Biol Ther; 2018 Jul; 18(sup1):99-104. PubMed ID: 30063853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymosin β4: a potential novel dry eye therapy.
    Sosne G; Qiu P; Ousler GW; Dunn SP; Crockford D
    Ann N Y Acad Sci; 2012 Oct; 1270():45-50. PubMed ID: 23050816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymosin beta4 and corneal wound healing: visions of the future.
    Sosne G; Qiu P; Kurpakus-Wheater M; Matthew H
    Ann N Y Acad Sci; 2010 Apr; 1194():190-8. PubMed ID: 20536468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis.
    Sosne G; Berger EA
    Int Immunopharmacol; 2023 May; 118():109953. PubMed ID: 37018981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymosin β4 significantly reduces the signs of dryness in a murine controlled adverse environment model of experimental dry eye.
    Sosne G; Kim C; Kleinman HK
    Expert Opin Biol Ther; 2015; 15 Suppl 1():S155-61. PubMed ID: 26096547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymosin-beta4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury.
    Sosne G; Christopherson PL; Barrett RP; Fridman R
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2388-95. PubMed ID: 15980226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
    Sosne G; Dunn SP; Kim C
    Cornea; 2015 May; 34(5):491-6. PubMed ID: 25826322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymosin beta-4 and the eye: I can see clearly now the pain is gone.
    Sosne G; Qiu P; Kurpakus-Wheater M
    Ann N Y Acad Sci; 2007 Sep; 1112():114-22. PubMed ID: 17495249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye.
    Nagelhout TJ; Gamache DA; Roberts L; Brady MT; Yanni JM
    J Ocul Pharmacol Ther; 2005 Apr; 21(2):139-48. PubMed ID: 15857280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4.
    Dunn SP; Heidemann DG; Chow CY; Crockford D; Turjman N; Angel J; Allan CB; Sosne G
    Ann N Y Acad Sci; 2010 Apr; 1194():199-206. PubMed ID: 20536469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The cornea: stasis and dynamics].
    Nishida T
    Nippon Ganka Gakkai Zasshi; 2008 Mar; 112(3):179-212; discussion 213. PubMed ID: 18411711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone.
    Zagon IS; Sassani JW; Immonen JA; McLaughlin PJ
    Clin Exp Ophthalmol; 2014 Mar; 42(2):159-68. PubMed ID: 23777539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of second-hand cigarette smoke-induced impairment of corneal wound healing by thymosin beta4 combined with anti-inflammatory agents.
    Yuan H; Ma C; Moinet L; Sato N; Martins-Green M
    Invest Ophthalmol Vis Sci; 2010 May; 51(5):2424-35. PubMed ID: 20019366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cellular mechanisms of dry eye: from pathogenesis to treatment.
    Mantelli F; Massaro-Giordano M; Macchi I; Lambiase A; Bonini S
    J Cell Physiol; 2013 Dec; 228(12):2253-6. PubMed ID: 23696296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
    Toker E; Asfuroğlu E
    Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The practical detection of mmp-9 diagnoses ocular surface disease and may help prevent its complications.
    Kaufman HE
    Cornea; 2013 Feb; 32(2):211-6. PubMed ID: 22673852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous serum for ocular surface diseases.
    Quinto GG; Campos M; Behrens A
    Arq Bras Oftalmol; 2008; 71(6 Suppl):47-54. PubMed ID: 19274411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neurotrophic keratopathy--a post-LASIK case report].
    Fuchsluger TA; Steuhl KP; Meller D
    Klin Monbl Augenheilkd; 2005 Nov; 222(11):901-4. PubMed ID: 16308823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.